Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

clemcaldwell 91 posts  |  Last Activity: Jul 2, 2015 3:14 PM Member since: Jul 7, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • clemcaldwell by clemcaldwell May 15, 2015 1:01 PM Flag

    I spoke to people at Exelixis. They told me they had talked to that guy after his report. He doesn't understand; is what I was told. Also they told me to be patient and June 1st etc. we will hear the true results, to date, for Metero and the Roche trials. Orals will be right up to the moment and add info. the Abstracts don't contain. So there you have it. If you want facts or question some reports or post by outsiders go to the source; Exel.

  • Reply to

    E1512

    by wilderguide Apr 16, 2015 5:14 PM
    clemcaldwell clemcaldwell Apr 17, 2015 4:06 PM Flag

    Geneva, Switzerland, 17 April 2015 -- A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

    Dr. Oliver Gautschi, a medical oncologist from Lucern Cantonal Hospital in Switzerland, presented the results of the retrospective EURAF cohort study, which included lung cancer patients whose tumours carried specific mutations in the BRAF gene. The study was conducted by a network of European oncologists, without company involvement.

    BRAF mutations are commonly seen in melanoma patients, and are found in about 2% of lung adenocarcinomas, Gautschi explains. Several inhibitors of the B-Raf protein, including vemurafenib and dabrafenib, have been developed for use in melanoma patients, however there is currently no approved drug for BRAF-mutant lung cancer.

    As a result, experience with B-Raf inhibitors in lung cancer remains limited. "In the current study, we wanted to find out how many patients in Europe received B-Raf inhibitors outside of a clinical trial, and what their outcomes were," Gautschi says.

    The EURAF study gathered information on 35 lung cancer patients who had been identified as carrying BRAF mutations, who were treated with B-Raf inhibitors between 2012 and 2014.

    Most of those patients received vemurafenib, some dabrafenib, and one sorafenib. Overall response rate was 53% as measured by the widely used Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. Overall, progression-free survival time in this group was 5 months.

    Most patients were pretreated, and not eligible for enrolment in a clinical trial, which means these results are encouraging, the researchers say, although the study's small size and retrospective nature mean the analysis of the magnitude of benefit should be treated cautiously.

    "The bottom line is that clinicians should be sure to test patients for so-called 'rare' driver mutations in lung cancer, because individual patients may derive substantial benefit from targeted therapy," says Gautschi.

    Commenting on the findings, Dr David Planchard, pulmonary oncologist at Gustave Roussy in Villejuif, France, said that the results of the trial confirm the benefit of B-Raf inhibitors in BRAF-mutant non-small cell lung cancer. The current trial also confirmed the good tolerance of the drugs with no new side-effects, he said. Planchard and colleagues have presented a separate phase II study in this area with dabrafenib [1].

    "This trial is important because due to the low frequency of this mutation in non-small cell lung cancer we will have few trials on this population," Planchard commented. "The more data we have, the better we understand how important it is to test for the mutation, especially in adenocarcinomas, and to expose mutation-positive patients to a specific B-Raf inhibitor."

    The results also add to growing support for the approval of B-Raf inhibitors for use in lung cancer, Planchard added. This is important because the rarity of this mutation means that performing the kind of randomized phase III trials usually required for licensing approval will be extremely difficult, he noted.

    Looking ahead, it will also be important to see results of combination therapy with inhibitors of B-Raf and a related protein, Mek, in non-small cell lung cancer carrying BRAF-V600E mutations, the researchers note, as this combination has shown a higher clinical benefit in BRAF-mutant melanoma.

  • May 13, 2015, 5:00 PM (EDT) - All Publication-Only abstracts from the 2015 ASCO Annual Meeting will be publicly released on abstracts.asco.org.

  • Reply to

    Stifel

    by clemcaldwell May 15, 2015 1:01 PM
    clemcaldwell clemcaldwell May 15, 2015 1:58 PM Flag

    Wrong! Wrong! Wrong! I have talked to people other than IR. I did work there for 10yrs.. I won't get info. others can't get. But the first 2 sentences are exactly what I was told. The other thing is I was told too be patient and we will hear more June 1st.

  • Reply to

    Stifel

    by clemcaldwell May 15, 2015 1:01 PM
    clemcaldwell clemcaldwell May 16, 2015 12:37 PM Flag

    I made a mistake I wasn't told Metero. My mind slipped again. Sorry. I was told Cabo and Cobi info. would be given. June 1st was said to be the day to take note of what is made available.

  • clemcaldwell by clemcaldwell Apr 9, 2015 3:40 PM Flag

    From Street article: With the designation, cabozantinib is now also eligible for a Priority Review of a New Drug Application.Nothing but good news today.That's why the price rose today.There is no getting around that fact.

  • Reply to

    The Street - EXEL is "chart of the day"

    by nomad_1957 Apr 16, 2015 10:41 AM
    clemcaldwell clemcaldwell Apr 16, 2015 2:52 PM Flag

    Back in 2008 or 2009, I believe you used the handle nomad_celcius12. You posted incessantly venomous comment after comment. Nothing but your personal opinions without merit .You just wasted your time.Then you stopped after about 5 years.Now your back as nomad_1957;posting the same kind of worthless nonsense.

  • clemcaldwell by clemcaldwell Apr 17, 2015 4:29 PM Flag

    The NASDAQ Biotechnology Index was -1.42%. The major index were creamed today. While Exel rose a penny.

  • Reply to

    Stifel

    by clemcaldwell May 15, 2015 1:01 PM
    clemcaldwell clemcaldwell May 15, 2015 1:42 PM Flag

    He may have an agenda. Or he may not. 1 of lifes mysteries, if you ask me, trying to understand someone else. There sure are lots of worthless post here. That I'm sure of. Why would someone try to sell people on some stocks or a Website perporting to help people make a fortune on stocks is beyound me. Then people with posts that do nothing but say it's going green today or it will be at $5 by close. Such a waste of time, worhtless junk. Oh well there is no accounting for stupidity. Of course sometimes I also make mistakes; I'm not perfect.

  • Reply to

    SA article

    by tm171717 Jun 25, 2015 4:40 PM
    clemcaldwell clemcaldwell Jun 26, 2015 3:53 PM Flag

    What a bounce! Down 31 cents earlier. Now minus 7 cents. Crazy!

  • Reply to

    BRAF V600E

    by stimulustrader Jul 1, 2015 11:33 AM
    clemcaldwell clemcaldwell Jul 1, 2015 1:15 PM Flag

    Maybe in 10 yrs. time. Maybe not. Many new treatment attempts have come and gone without fruitation.

  • Reply to

    Fasttrack, and what it means.

    by oncodoc02138 Apr 9, 2015 1:29 PM
    clemcaldwell clemcaldwell Apr 9, 2015 3:00 PM Flag

    I like this part:"Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients."

  • Reply to

    AACR MEETING 2015

    by saltydog711 Apr 19, 2015 10:46 AM
    clemcaldwell clemcaldwell Apr 19, 2015 2:34 PM Flag

    Nice so far in Mice tests.

  • Reply to

    Wow, important line from report!!!

    by alexp1112 Apr 30, 2015 4:26 PM
    clemcaldwell clemcaldwell Apr 30, 2015 4:38 PM Flag

    As valley said; no one knows until the results are in. Until then it is all guessing.

  • Reply to

    May 13, 2015 abstracts released

    by clemcaldwell May 11, 2015 1:33 PM
    clemcaldwell clemcaldwell May 12, 2015 12:44 PM Flag

    Go to the ASCO homepage and work your way around the site. It may answer many questions you have. It's easy. Good luck.

  • Reply to

    MANIPULATION

    by saltydog711 May 21, 2015 12:18 PM
    clemcaldwell clemcaldwell May 21, 2015 6:51 PM Flag

    AVEO has similar manipulation I guess. Day's Range: 1.81 - 3.50, Prev Close: 1.60, Close 2.23 Up 0.63(39.38%) 4:00PM EDT. Or is it just profit taking; like IR told me is what is happening with Exel. Profit taking of pennies not dollars? I didn't like that answer.

  • Reply to

    8 dollars next week

    by bugbgon May 30, 2015 10:25 PM
    clemcaldwell clemcaldwell Jun 1, 2015 1:06 PM Flag

    What an genius. It sure doesn't look like it's moving to $8 or even $4; like another said it would. Now tell me what the outcome of the NBA final will be. And by how many points the games will be won by. It's ridiculous and point less telling the world what you think the price will be.

  • Reply to

    BRAF V600E

    by stimulustrader Jul 1, 2015 11:33 AM
    clemcaldwell clemcaldwell Jul 2, 2015 1:20 PM Flag

    Seattle Genetics has been around since about 1997. They have been trying to find drugs to combat cancer using monoclonal antibody therapy, a form of immunotherapy, and have one approved drug; ADCETRIS. So you see it is not so easy or even clear that the hype will prove to reap many quick, or any great number of successes.

  • Reply to

    3rd Quarter is Here

    by duckduffer Jul 2, 2015 2:53 PM
    clemcaldwell clemcaldwell Jul 2, 2015 3:14 PM Flag

    If not over a Holiday weekend.Monday would be outstanding. It should be soon. I'll be trickled pink if it happens to be great news and maybe beats all guesses. I've waited long enough after a $12 or higher price to the price slide that took us where we are today. Cheers!

  • Reply to

    Fasttrack, and what it means.

    by oncodoc02138 Apr 9, 2015 1:29 PM
    clemcaldwell clemcaldwell Apr 9, 2015 4:07 PM Flag

    Wrong.Of course I know the Fast Track is a 6 month process.Fast Track acceptance is not a given as you said.

EXEL
3.44-0.05(-1.43%)Jul 2 4:00 PMEDT